Letters Section Editor: Robert M. Golub, MD, Senior Editor.
To the Editor: Dr Pedersen and colleagues1 conclude that while high-dose atorvastatin for secondary prevention of coronary artery disease following acute myocardial infarction produced no statistically significant decrease in all-cause or cardiovascular mortality compared with usual-dose simvastatin, the lack of a difference between the 2 groups in adverse events classified as serious implies that patients with established coronary artery disease may benefit from intensive lipid lowering without serious adverse events.
Cayley WE. High-Dose Statins and the IDEAL Study. JAMA. 2006;295(21):2476-2479. doi:10.1001/jama.295.21.2476-b